Drug Profile
Rabies vaccine - Simcere pharmaceuticals
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Jiangsu Yanshen
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Rabies
Most Recent Events
- 06 May 2016 Jiangsu Simcere Pharmaceutical completes a phase III trial in Healthy volunteers in China (ChiCTR-PPR15007057)
- 26 May 2009 Clinical trials in Rabies in China (Parenteral) before May 2006
- 26 May 2009 Registered for Rabies in China (Parenteral)